22.501759002225988," BRIEF-Unum Group Files Prospectus Supplement Related To A Potential Senior Notes Due 2025 Offering May 18 (Reuters) - Unum Group: * UNUM GROUP FILES PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL SENIOR NOTES DUE 2025 OFFERING - SEC FILING * UNUM GROUP - THE SENIOR NOTES WILL MATURE ON MARCH 15, 2025 * UNUM GROUP - SENIOR NOTES ARE ISSUABLE IN DENOMINATIONS OF $2,000 AND INTEGRAL MULTIPLES OF $1,000 IN EXCESS THEREOF Source text - bit.ly/3cJZSyH Further company coverage:"
38.435091201958706," BRIEF-Unum Therapeutics Says Terminated Employment Of Matthew Osborne, CFO, Effective As Of May 29 May 15 (Reuters) - Unum Therapeutics Inc: * UNUM THERAPEUTICS - ON MAY 14, TERMINATED EMPLOYMENT OF MATTHEW OSBORNE, CO'S CHIEF FINANCIAL OFFICER, EFFECTIVE AS OF MAY 29, 2020 Source text: (bit.ly/2T5RbHi) Further company coverage:"
1.1734112033058028," BRIEF-Unum Group Q1 Adjusted Operating Earnings Per Share $1.35 Unum Group: * Q1 EARNINGS PER SHARE ESTIMATE $1.38 -- REFINITIV IBES DATA * BOOK VALUE PER COMMON SHARE AS OF MARCH 31, 2020 WAS $48.21, COMPARED TO $42.68 AT MARCH 31, 2019 * QTRLY TOTAL REVENUE $2,871.1 MILLION VERSUS $2,987.6 MILLION * DUE TO UNCERTAIN ECONOMIC ENVIRONMENT CAUSED BY COVID-19 PANDEMIC, COMPANY IS SUSPENDING ITS FINANCIAL GUIDANCE FOR REMAINDER OF 2020 * CO HAS SUSPENDED ITS CURRENT SHARE REPURCHASE AUTHORIZATION AND WILL NOT REPURCHASE SHARES IN 2020 * CO INTENDS TO CONTINUE TO PAY ITS COMMON STOCK DIVIDEND AT THE CURRENT RATE * SAYS CANNOT FULLY ESTIMATE THE ULTIMATE IMPACT OF THE COVID-19 PANDEMIC AT THIS TIME Source text for Eikon: Further company coverage:"
-0.35198841651190016," BRIEF-Unum Therapeutics Reports Q4 Loss Per Share $0.07 March 26 (Reuters) - Unum Therapeutics Inc: * UNUM THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES * Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA * UNUM THERAPEUTICS - POTENTIAL STRATEGIC ALTERNATIVES THAT MAY BE EVALUATED INCLUDE, BUT ARE NOT LIMITED TO, ACQUISITION, MERGER, BUSINESS COMBINATION * UNUM THERAPEUTICS- POTENTIAL STRATEGIC ALTERNATIVES THAT MAY BE EVALUATED INCLUDE, BUT ARE NOT LIMITED TO, IN-LICENSING, OTHER STRATEGIC TRANSACTION Source text for Eikon: Further company coverage:"
59.11850839495906, BRIEF-Unum Therapeutics Announces Common Stock Purchase Agreement For Up To $25 Mln With Lincoln Park Capital March 20 (Reuters) - Unum Therapeutics Inc: * UNUM THERAPEUTICS ANNOUNCES COMMON STOCK PURCHASE AGREEMENT FOR UP TO $25 MILLION WITH LINCOLN PARK CAPITAL Source text for Eikon: Further company coverage:
-5.813142778308995, BRIEF-Unum Group Files Preliminary Prospectus Supplement Related To Potential Junior Subordinated Notes Due 2058 Offering May 21 (Reuters) - Unum Group: * UNUM GROUP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL JUNIOR SUBORDINATED NOTES DUE 2058 OFFERING - SEC FILING Source text - (bit.ly/2rXDDjr) Further company coverage:
-18.240702918843752, BRIEF-Unum Group Q1 Earnings Per Share $1.23 May 1 (Reuters) - Unum Group: * Q1 EARNINGS PER SHARE VIEW $1.25 -- THOMSON REUTERS I/B/E/S * CONTINUES TO EXPECT AFTER-TAX ADJUSTED OPERATING INCOME GROWTH PER SHARE FOR 2018 TO BE WITHIN RANGE OF 17 PERCENT TO 23 PERCENT Source text for Eikon: Further company coverage:
-18.240702918843752, BRIEF-Unum Group Q1 Earnings Per Share $1.23 Unum Group: * Q1 EARNINGS PER SHARE VIEW $1.25 -- THOMSON REUTERS I/B/E/S * CONTINUES TO EXPECT AFTER-TAX ADJUSTED OPERATING INCOME GROWTH PER SHARE FOR 2018 TO BE WITHIN RANGE OF 17 PERCENT TO 23 PERCENT Source text for Eikon: Further company coverage:
